H. pylori eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): A prospective cohort study

Juan Alfonso Soler, Mercé Güell, Meritxell Bricullé, Antoni Gavarró, Imma Roig, Jordi Sanchez, Javier P. Gisbert, Pilar García, Albert Villoria, Xavier Calvet

Producción científica: Contribución a una revistaArtículoInvestigaciónrevisión exhaustiva

6 Citas (Scopus)

Resumen

Monoclonal gammopathy of unknown significance (MGUS) is a chronic haematological alteration that carries a 1% risk per year of malignant evolution. The origin of this disturbance remains unknown. Previous reports have suggested that a subgroup of patients presenting MGUS might cure after Helicobacter pylori eradication. This study evaluates the effect of H. pylori eradication in a cohort of 30 patients with MGUS. A 7-day clarithromycin-based triple treatment was prescribed to patients with MGUS infected with H. pylori. Quantification of the monoclonal component was performed at inclusion and at least 12 months after treatment. The monoclonal component persisted unchanged in all patients who cured the H. pylori infection. © Springer-Verlag 2009.
Idioma originalInglés
Páginas (desde-hasta)769-773
PublicaciónAnnals of Hematology
Volumen88
DOI
EstadoPublicada - 23 ene 2009

Huella

Profundice en los temas de investigación de 'H. pylori eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): A prospective cohort study'. En conjunto forman una huella única.

Citar esto